Global GMPs: How Much Faith Will FDA Put In Private Third-Party Audits?
Executive Summary
Private and third-party audits may not replace FDA’s typical inspection duties, but could help direct the agency to problematic facilities and relieve some of the inspection burden on those that already are compliant.
You may also be interested in...
Compounding Oversight: Could Third-Party Inspection Solve The Problem?
Iowa has contracted with a national pharmacy group to inspect facilities outside its borders. Although the program could serve as a potential model for a nationwide plan, it also could bring several problems.
GMP Third-Party Audits Offered In Draft Senate User Fee Legislation
Bipartisan group of senators unveils several draft provisions of user fee legislation, including a program to allow third-party auditors to evaluate manufacturing facility compliance with U.S. standards for drugs.
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.